These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

350 related items for PubMed ID: 36918743

  • 1. Simultaneous and divergent evolution of resistance to cephalosporin/β-lactamase inhibitor combinations and imipenem/relebactam following ceftazidime/avibactam treatment of MDR Pseudomonas aeruginosa infections.
    Alonso-García I, Vázquez-Ucha JC, Lasarte-Monterrubio C, González-Mayo E, Lada-Salvador P, Vela-Fernández R, Aja-Macaya P, Guijarro-Sánchez P, Rumbo-Feal S, Muíño-Andrade M, Fernández-González A, Martínez-Guitián M, Beceiro A, Rodríguez-Iglesias M, Oliver A, Arca-Suárez J, Galán-Sánchez F, Bou G.
    J Antimicrob Chemother; 2023 May 03; 78(5):1195-1200. PubMed ID: 36918743
    [Abstract] [Full Text] [Related]

  • 2. Activity of cefiderocol, imipenem/relebactam, cefepime/taniborbactam and cefepime/zidebactam against ceftolozane/tazobactam- and ceftazidime/avibactam-resistant Pseudomonas aeruginosa.
    Lasarte-Monterrubio C, Fraile-Ribot PA, Vázquez-Ucha JC, Cabot G, Guijarro-Sánchez P, Alonso-García I, Rumbo-Feal S, Galán-Sánchez F, Beceiro A, Arca-Suárez J, Oliver A, Bou G.
    J Antimicrob Chemother; 2022 Sep 30; 77(10):2809-2815. PubMed ID: 35904000
    [Abstract] [Full Text] [Related]

  • 3. Comparative activity of newer β-lactam/β-lactamase inhibitor combinations against Pseudomonas aeruginosa isolates from US medical centres (2020-2021).
    Sader HS, Mendes RE, Arends SJR, Carvalhaes CG, Shortridge D, Castanheira M.
    Int J Antimicrob Agents; 2023 Apr 30; 61(4):106744. PubMed ID: 36738849
    [Abstract] [Full Text] [Related]

  • 4. Comparison of In Vitro Activity of Ceftazidime-Avibactam and Imipenem-Relebactam against Clinical Isolates of Pseudomonas aeruginosa.
    Wang L, Zhang X, Zhou X, Yang F, Guo Q, Wang M.
    Microbiol Spectr; 2023 Jun 15; 11(3):e0093223. PubMed ID: 37199669
    [Abstract] [Full Text] [Related]

  • 5. Selection of AmpC β-Lactamase Variants and Metallo-β-Lactamases Leading to Ceftolozane/Tazobactam and Ceftazidime/Avibactam Resistance during Treatment of MDR/XDR Pseudomonas aeruginosa Infections.
    Ruedas-López A, Alonso-García I, Lasarte-Monterrubio C, Guijarro-Sánchez P, Gato E, Vázquez-Ucha JC, Vallejo JA, Fraile-Ribot PA, Fernández-Pérez B, Velasco D, Gutiérrez-Urbón JM, Oviaño M, Beceiro A, González-Bello C, Oliver A, Arca-Suárez J, Bou G.
    Antimicrob Agents Chemother; 2022 Feb 15; 66(2):e0206721. PubMed ID: 34930034
    [Abstract] [Full Text] [Related]

  • 6. Antimicrobial activities of ceftazidime/avibactam, ceftolozane/tazobactam, imipenem/relebactam, meropenem/vaborbactam, and comparators against Pseudomonas aeruginosa from patients with skin and soft tissue infections.
    Sader HS, Castanheira M, Duncan LR, Mendes RE.
    Int J Infect Dis; 2021 Dec 15; 113():279-281. PubMed ID: 34670144
    [Abstract] [Full Text] [Related]

  • 7. Molecular mechanisms driving the in vivo development of OXA-10-mediated resistance to ceftolozane/tazobactam and ceftazidime/avibactam during treatment of XDR Pseudomonas aeruginosa infections.
    Arca-Suárez J, Lasarte-Monterrubio C, Rodiño-Janeiro BK, Cabot G, Vázquez-Ucha JC, Rodríguez-Iglesias M, Galán-Sánchez F, Beceiro A, González-Bello C, Oliver A, Bou G.
    J Antimicrob Chemother; 2021 Jan 01; 76(1):91-100. PubMed ID: 33083833
    [Abstract] [Full Text] [Related]

  • 8. Impact of chromosomally encoded resistance mechanisms and transferable β-lactamases on the activity of cefiderocol and innovative β-lactam/β-lactamase inhibitor combinations against Pseudomonas aeruginosa.
    González-Pinto L, Alonso-García I, Blanco-Martín T, Camacho-Zamora P, Fraile-Ribot PA, Outeda-García M, Lasarte-Monterrubio C, Guijarro-Sánchez P, Maceiras R, Moya B, Juan C, Vázquez-Ucha JC, Beceiro A, Oliver A, Bou G, Arca-Suárez J.
    J Antimicrob Chemother; 2024 Oct 01; 79(10):2591-2597. PubMed ID: 39073766
    [Abstract] [Full Text] [Related]

  • 9. In Vitro Activity of Ceftolozane-Tazobactam, Imipenem-Relebactam, Ceftazidime-Avibactam, and Comparators against Pseudomonas aeruginosa Isolates Collected in United States Hospitals According to Results from the SMART Surveillance Program, 2018 to 2020.
    Karlowsky JA, Lob SH, DeRyke CA, Hilbert DW, Wong MT, Young K, Siddiqui F, Motyl MR, Sahm DF.
    Antimicrob Agents Chemother; 2022 May 17; 66(5):e0018922. PubMed ID: 35491836
    [Abstract] [Full Text] [Related]

  • 10. Comparative activity of newer β-lactam/β-lactamase inhibitor combinations against Pseudomonas aeruginosa from patients hospitalized with pneumonia in European medical centers in 2020.
    Sader HS, Carvalhaes CG, Shortridge D, Castanheira M.
    Eur J Clin Microbiol Infect Dis; 2022 Feb 17; 41(2):319-324. PubMed ID: 34657213
    [Abstract] [Full Text] [Related]

  • 11. Phylogenetic analysis of resistance to ceftazidime/avibactam, ceftolozane/tazobactam and carbapenems in piperacillin/tazobactam-resistant Pseudomonas aeruginosa from cystic fibrosis patients.
    Zamudio R, Hijazi K, Joshi C, Aitken E, Oggioni MR, Gould IM.
    Int J Antimicrob Agents; 2019 Jun 17; 53(6):774-780. PubMed ID: 30831233
    [Abstract] [Full Text] [Related]

  • 12. Susceptibility of Multidrug-Resistant Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa from Germany to Ceftolozane-Tazobactam, Ceftazidime-Avibactam, and Imipenem-Relebactam.
    Kresken M, Wohlfarth E, Wichelhaus TA, Gatermann SG, Pfennigwerth N, Eisfeld J, Seifert H, German BL/BLI Study Group.
    Microb Drug Resist; 2023 Apr 17; 29(4):138-144. PubMed ID: 36622756
    [Abstract] [Full Text] [Related]

  • 13. Activity of newest generation β-lactam/β-lactamase inhibitor combination therapies against multidrug resistant Pseudomonas aeruginosa.
    Haines RR, Putsathit P, Hammer KA, Tai AS.
    Sci Rep; 2022 Oct 07; 12(1):16814. PubMed ID: 36207358
    [Abstract] [Full Text] [Related]

  • 14. Molecular characterization of clinically isolated Pseudomonas aeruginosa with varying resistance to ceftazidime-avibactam and ceftolozane-tazobactam collected as a part of the ATLAS global surveillance program from 2020 to 2021.
    Li H, Oliver A, Shields RK, Kamat S, Stone G, Estabrook M.
    Antimicrob Agents Chemother; 2024 Oct 08; 68(10):e0067024. PubMed ID: 39254297
    [Abstract] [Full Text] [Related]

  • 15. ESBLs and resistance to ceftazidime/avibactam and ceftolozane/tazobactam combinations in Escherichia coli and Pseudomonas aeruginosa.
    Ortiz de la Rosa JM, Nordmann P, Poirel L.
    J Antimicrob Chemother; 2019 Jul 01; 74(7):1934-1939. PubMed ID: 31225611
    [Abstract] [Full Text] [Related]

  • 16. Challenging Antimicrobial Susceptibility and Evolution of Resistance (OXA-681) during Treatment of a Long-Term Nosocomial Infection Caused by a Pseudomonas aeruginosa ST175 Clone.
    Arca-Suárez J, Fraile-Ribot P, Vázquez-Ucha JC, Cabot G, Martínez-Guitián M, Lence E, González-Bello C, Beceiro A, Rodríguez-Iglesias M, Galán-Sánchez F, Bou G, Oliver A.
    Antimicrob Agents Chemother; 2019 Oct 01; 63(10):. PubMed ID: 31383659
    [Abstract] [Full Text] [Related]

  • 17. Loss of activity of ceftazidime-avibactam due to MexAB-OprM efflux and overproduction of AmpC cephalosporinase in Pseudomonas aeruginosa isolated from patients suffering from cystic fibrosis.
    Chalhoub H, Sáenz Y, Nichols WW, Tulkens PM, Van Bambeke F.
    Int J Antimicrob Agents; 2018 Nov 01; 52(5):697-701. PubMed ID: 30081137
    [Abstract] [Full Text] [Related]

  • 18. Comparative analysis of in vitro dynamics and mechanisms of ceftolozane/tazobactam and imipenem/relebactam resistance development in Pseudomonas aeruginosa XDR high-risk clones.
    Gomis-Font MA, Cabot G, López-Argüello S, Zamorano L, Juan C, Moyá B, Oliver A.
    J Antimicrob Chemother; 2022 Mar 31; 77(4):957-968. PubMed ID: 35084040
    [Abstract] [Full Text] [Related]

  • 19. Multicenter Evaluation of Ceftazidime-Avibactam and Ceftolozane-Tazobactam Inhibitory Activity against Meropenem-Nonsusceptible Pseudomonas aeruginosa from Blood, Respiratory Tract, and Wounds.
    Grupper M, Sutherland C, Nicolau DP.
    Antimicrob Agents Chemother; 2017 Oct 31; 61(10):. PubMed ID: 28739780
    [Abstract] [Full Text] [Related]

  • 20. Activity of imipenem/relebactam and comparators against KPC-producing Klebsiella pneumoniae and imipenem-resistant Pseudomonas aeruginosa.
    Delgado-Valverde M, Portillo-Calderón I, Alcalde-Rico M, Conejo MC, Hidalgo C, Del Toro Esperón C, Pascual Á.
    Eur J Clin Microbiol Infect Dis; 2024 Mar 31; 43(3):445-457. PubMed ID: 38157139
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.